# Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

> **NCT03896984** · — · COMPLETED · sponsor: **Bayer** · enrollment: 346 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Radium-223 (Xofigo, BAY88-8223)
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03896984
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2020-06-08
- **Final completion:** 2020-12-14
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896984, "Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03896984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*